Analysis links SERMs to breast cancer prevention benefit

05/1/2013 | MyHealthNewsDaily.com · PhysiciansBriefing.com

Taking selective estrogen receptor modulators such as tamoxifen and raloxifene after menopause reduces by 38% a woman's risk of developing any kind of breast cancer for 10 years, according to an analysis of data from nine studies. The estrogen-blocking drugs particularly lowered the risk of estrogen-receptor positive breast cancer, researchers found. The study appeared online in The Lancet.

View Full Article in:

MyHealthNewsDaily.com · PhysiciansBriefing.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory FDA
Cardinal Health
Columbus, OH
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA